Literature DB >> 8393050

Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA.

K R Jerome1, N Domenech, O J Finn.   

Abstract

Human breast and pancreatic adenocarcinomas are tumors of ductal epithelial cell origin and as such produce and express on their surface polymorphic epithelial cell mucin encoded by the MUC 1 gene. We have previously reported that tumor-specific cytotoxic T cells derived from patients bearing such tumors recognize specific epitopes on the mucin polypeptide core. This recognition was not MHC-restricted because of the highly repetitive sequence of the polypeptide core, which allows simultaneous recognition of many identical epitopes, and cross-linking and aggregation of TCR on mucin-specific T cells. Those studies were performed with limited numbers of tumor cells or allogeneic tumor cell lines. A renewable source of autologous cells presenting this Ag was necessary to further explore mucin-specific immunity. We report here successful establishment and functional analysis of mucin-specific CTL lines and clones derived from breast and pancreatic cancer patients, using either autologous or allogeneic mucin-transfected B cells as Ag. Our results demonstrate that transfection of autologous or allogeneic B cells with mucin confers upon them tumor Ag-presenting ability as well as susceptibility to lysis by mucin-specific CTL. Transfection of APC with this or any other human tumor Ag that may be molecularly defined in the future provides a unique and powerful tool with which to examine the ability of a tumor-associated Ag to stimulate T cell responses.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8393050

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  44 in total

1.  Towards immunotherapy of pancreatic cancer.

Authors:  I F McKenzie; V Apostolopoulos
Journal:  Gut       Date:  1999-06       Impact factor: 23.059

Review 2.  L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review.

Authors:  Wenjie Xia; Jie Wang; Youtao Xu; Feng Jiang; Lin Xu
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

Review 3.  Epidemiologic perspective on immune-surveillance in cancer.

Authors:  Daniel W Cramer; Olivera J Finn
Journal:  Curr Opin Immunol       Date:  2011-02-01       Impact factor: 7.486

Review 4.  Mucin glycoproteins in neoplasia.

Authors:  Y S Kim; J Gum; I Brockhausen
Journal:  Glycoconj J       Date:  1996-10       Impact factor: 2.916

5.  Differential expression of MUC1 on transfected cell lines influences its recognition by MUC1 specific T cells.

Authors:  J Magarian-Blander; R P Hughey; C Kinlough; P A Poland; O J Finn
Journal:  Glycoconj J       Date:  1996-10       Impact factor: 2.916

6.  Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses.

Authors:  V Apostolopoulos; G A Pietersz; B E Loveland; M S Sandrin; I F McKenzie
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

7.  Suppressive effects of tumor cell-derived 5'-deoxy-5'-methylthioadenosine on human T cells.

Authors:  Frederik C Henrich; Katrin Singer; Kerstin Poller; Luise Bernhardt; Carolin D Strobl; Katharina Limm; Axel P Ritter; Eva Gottfried; Simon Völkl; Benedikt Jacobs; Katrin Peter; Dimitrios Mougiakakos; Katja Dettmer; Peter J Oefner; Anja-Katrin Bosserhoff; Marina P Kreutz; Michael Aigner; Andreas Mackensen
Journal:  Oncoimmunology       Date:  2016-06-10       Impact factor: 8.110

8.  MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study.

Authors:  Takashi Kimura; John R McKolanis; Lynda A Dzubinski; Kazi Islam; Douglas M Potter; Andres M Salazar; Robert E Schoen; Olivera J Finn
Journal:  Cancer Prev Res (Phila)       Date:  2012-12-17

9.  Induction of cellular immunity in chimpanzees to human tumor-associated antigen mucin by vaccination with MUC-1 cDNA-transfected Epstein-Barr virus-immortalized autologous B cells.

Authors:  G Pecher; O J Finn
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

Review 10.  Bridging innate and adaptive antitumor immunity targeting glycans.

Authors:  Anastas Pashov; Bejatolah Monzavi-Karbassi; Gajendra P S Raghava; Thomas Kieber-Emmons
Journal:  J Biomed Biotechnol       Date:  2010-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.